Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
Clin Endocrinol (Oxf). 2012 Feb;76(2):297-303. doi: 10.1111/j.1365-2265.2011.04204.x.
To investigate the cure rate and incidence of hypothyroidism of radioiodine treatment with a calculated dose regimen and an intended thyroid dose of 150 Gy in patients with toxic nodular goitre during long-term follow-up.
A total of 265 consecutive patients with toxic nodular goitre were treated between March 2003 and August 2004 at our institute and followed up for a maximum of 8 years. Preliminary radioiodine testing with volumetric measurement of the thyroid by ultrasound as well as individual thyroidal radioiodine uptake and half-life measurements were performed before radioiodine therapy. The estimated radiation dose to the thyroid was 150 Gy.
Follow-up controls with respect to success of therapy and development of hypothyroidism were performed 3 months, 1 and up to 8 years after radioiodine treatment. The relation of the achieved thyroid dose to the success rate of treatment and to the incidence of hypothyroidism was analysed.
The cure rates were 85% at 3 months, 98% at 1 year and 98% at the end of follow-up. Above an achieved thyroid dose of more than 120 Gy, there was no significant association between the dose achieved in the thyroid and the cure rate on follow-up. The incidences of hypothyroidism at 3 months, at 1 year and at the end of follow-up were 32%, 55% and 73%, respectively.
Radioiodine treatment with a calculated dose regimen is a highly effective treatment option in patients with toxic goitre with an overall success rate of 98%. However, radioiodine treatment with an intended thyroid dose of 150 Gy leads to a high incidence of hypothyroidism on long-term follow-up. This finding supports the suggestion that in future intended thyroid doses could be lowered in patients treated with a calculated dose regimen for toxic nodular goitre.
探讨在长期随访中,采用计算剂量方案和 150Gy 甲状腺靶剂量对毒性结节性甲状腺肿患者进行放射性碘治疗的治愈率和甲状腺功能减退症发生率。
2003 年 3 月至 2004 年 8 月,我院共收治 265 例毒性结节性甲状腺肿患者,随访时间最长 8 年。放射性碘治疗前,行甲状腺超声体积测量、甲状腺摄取率和半衰期的初步放射性碘检测。估计甲状腺的辐射剂量为 150Gy。
放射性碘治疗后 3 个月、1 年和 8 年进行随访,观察治疗成功和甲状腺功能减退的情况。分析达到的甲状腺剂量与治疗成功率和甲状腺功能减退发生率的关系。
3 个月时的治愈率为 85%,1 年时为 98%,随访结束时为 98%。在达到的甲状腺剂量超过 120Gy 后,达到的甲状腺剂量与随访时的治愈率之间无显著相关性。3 个月、1 年和随访结束时甲状腺功能减退的发生率分别为 32%、55%和 73%。
采用计算剂量方案的放射性碘治疗是毒性甲状腺肿患者的一种非常有效的治疗选择,总成功率为 98%。然而,采用 150Gy 甲状腺靶剂量的放射性碘治疗会导致长期随访中甲状腺功能减退症的发生率较高。这一发现支持了以下建议:在未来,对于采用计算剂量方案治疗毒性结节性甲状腺肿的患者,可能需要降低预期的甲状腺剂量。